Epratuzumab Phase IIb Study Shows Positive Effect in Moderate to Severe S.L.E.

Lupus LA’s Dr. Dan Wallace Comments

ATLANTA – UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIb study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant* reduction in disease activity in adult patients with moderate to severe active SLE.